Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06988111

Management of Post-operative Respiratory Failure by Using NIV and High Velocity Nasal Insufflation (HVNI)

Postoperative respiratory failure (PORF) remains a critical driver of morbidity, mortality, and incremental care costs in surgical populations. Traditional escalation often involves invasive mechanical ventilation, which is associated with ventilator-associated pneumonia (VAP), prolonged intensive care unit (ICU) stays, and increased resource burden.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Assuit Univeristy

Asyut, Assuit, 71515, Egypt

Location status: Recruiting

Location contact

Ahmad M. Abd El-Hafez, MD

PRINCIPAL_INVESTIGATOR

Aliae A. Hussien, MD

PRINCIPAL_INVESTIGATOR

Maiada K. Hahem, MD

PRINCIPAL_INVESTIGATOR

ahmed M. Shaddad, MD

PRINCIPAL_INVESTIGATOR

ahmed M. shaddad, MD

CONTACT

[email protected]

+201111171930

CONTACT

[email protected]

About this study

Noninvasive ventilation (NIV) and high-flow nasal cannula (HFNC) have both been shown to improve oxygen levels effectively and reduce the need for reintubation in various patient groups. However, head-to-head data in patients with obstructive or restrictive pulmonary function (PORF) are scarce.

This protocol employs a robust and scalable design to generate high-quality evidence, empower perioperative stakeholders, and optimize patient-centric respiratory strategies. We hypothesize that NIV will reduce 72-hour reintubation rates compared to HFNC, translating into shorter ICU stays and lower costs.

Methodology & Operational Workflow

  • Screening & Consent Identify eligible patients in the post-anesthesia care unit (PACU) or ICU. Obtain informed consent from the patient or legal surrogate.
  • Baseline Assessment The baseline assessment includes demographics, comorbidities, and surgical data, as well as baseline arterial blood gases (ABG), vital signs, and comfort scores.
  • Randomization & Initiation Allocate via a secure web-based randomization module. Initiate assigned respiratory support within 30 minutes of notification.
  • Monitoring & Data Collection The patient is receiving continuous pulse oximetry and respiratory rate monitoring.

ABGs and fraction of inspired oxygen (FIO2) at 1 hour, 6 hours, and 24 hours. Comfort scores every six hours. Record interface-related adverse events.

  • Escalation Criteria The patient exhibits persistent partial arterial oxygen pressure/fraction of inspired oxygen ratio (PaO2/FiO2) levels of less than 100, even at maximal settings.

Hemodynamic instability occurs due to the use of new-onset vasopressors. Deterioration leading to invasive ventilation → classified as "reintubation."

  • Weaning Protocol. Transition to standard oxygen therapy when the flow or pressure is minimal.
  • Follow-Up & Discharge Track ICU length of stay (LOS), hospital LOS, and ventilation-free days (VFD). Keep a record of the 30-day survival rate and any readmissions.
  • Statistical Analysis Plan Primary Endpoint: Compare reintubation rates using a χ² test; report the risk difference and 95% confidence interval.
  • Missing Data: Multiple imputation for datasets with ≤ 5% missing data; sensitivity analysis for worst-case scenarios.
  • Interim Analysis: After 50% enrollment, the Data Safety and Monitoring Board (DSMB) reviews efficacy and futility, using O'Brien-Fleming boundaries.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age above 18 years
  • within 48 hours after major surgery
  • PAO2/FIO2 less than 200
  • Signs of respiratory distress and respiratory rate (RR) more than 25 cycles/minute

Exclusion criteria

  • Age below 18 years
  • Pregnant ladies
  • Orofacial trauma or burns
  • Active Gastrointestinal bleeding

Treatment and study plan

BiPAP

Device

The second arm (NIV group) will be managed by BIPAP device for post-operative respiratory failure

Vapotherm

Device

The first arm (HVNC group) will be managed by Vapotherm device for post-operative respiratory failure

Other names: High-velocity nasal insufflation, High velocity nasal cannula

Primary outcomes

  1. Weaning success

    Time frame: At 48 hours and then daily for 28 days.

    The primary outcome will be comparing the weaning success (in days) for both arms of the study group. This will be accessed after 48 hours and on a daily basis until the weaning criteria are met or for 28 days.

Study contacts

Contact information is provided by the study sponsor or research team.

Ahmad M. Shaddad, MD

CONTACT

[email protected]

+201111171930

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

A Prospective, Randomized Controlled Trial Comparing Noninvasive Ventilation (NIV) Versus High-Velocity Nasal Cannula (HVNC) in the Management of Acute Post-Operative Respiratory Failure

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
May 23, 2025
Registry last updated
Apr 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.